Telesis Bio’s stock surged in after-hours trading on Wednesday after announcing a partnership with Beckman Coulter Life Sciences to create efficient and scalable biofoundries for DNA synthesis. The partnership combines Telesis Bio’s cutting-edge Gibson SOLA technology with Beckman Coulter’s automation expertise, promising to transform the landscape of synthetic biology.